MRNA vaccine takes on genital herpes in first human trial
NCT ID NCT07330440
First seen Jan 10, 2026 · Last updated May 20, 2026 · Updated 30 times
Summary
This early-stage study tests an mRNA vaccine designed to prevent genital herpes caused by HSV-2. About 144 healthy adults aged 18-55 will receive different doses to check safety and immune response. The goal is to see if the vaccine is safe and prompts the body to fight the virus.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENITAL HERPES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Jishuitan Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.